CMR Surgical Ltd. yesterday announced that more than 30,000 surgical cases around the world have been completed using its Versius system. The Cambridge, U.K.-based company said this milestone solidifies its position as the second most-used soft-tissue surgical robot on the market.

"We are proud that over 30,000 patients around the world have now benefited from Versius, as we continue to grow and deliver against our mission of transforming surgery for good," stated Massimiliano Colella, the new CEO of CMR Surgical. "This milestone is thanks to the surgeons and hospitals who have adopted Versius with the aim of improving patient care and our dedicated employees who are committed to giving our customers the best experience."

Founded in 2014, CMR Surgical said it has designed Versius to fit into virtually any operating room and easily integrate into existing workflows for minimal access surgery (MAS). The company claimed that the system's portability and modular design allow surgeons to use only the number of arms needed for a given procedure.

CMR Surgical designed Versius to assist surgeons with minimally invasive procedures involving the lungs, thymus, and esophagus. The system won clearance from the U.S. Food and Drug Administration (FDA) in October 2024.

Biomimicking the human arm, Versius enables surgeons to optimize port placement for each patient and offers the dexterity and accuracy of small, fully wristed instruments, said CMR Surgical. The small-scale surgical robot features collaborative arms and bedside units for direct patient access.

The Versius Surgical System is intended to assist in the precise control of Versius Surgical endoscopic instruments such as rigid endoscopes, endoscopic dissectors, scissors, and forceps. It is designed to work with needle holders, electrosurgery, and accessories for endoscopic manipulation of tissue. Such manipulation includes grasping, cutting, blunt and sharp dissection, approximation, ligation, electrosurgery and suturing.

Early last year, CMR Surgical launched vLimeLite, an integrated fluorescence imaging system that works with its Versius Plus surgical robot. It is intended to help surgeons visually assess blood flow, vessels, and related tissue perfusion, as well as biliary anatomy.

The company also launched enhancements including the Ultrasonic Dissector late last year. It noted that the Ultrasonic Dissector and vLimeLite are CE- and UKCA-marked for certification in Europe and the U.K.

Versius' open surgeon console can reduce stress and fatigue and allows for clear communication with the surgical team, thanks to 3D HD vision, easy-to adopt instrument control, and a choice of ergonomic working positions, CMR asserted.

"By thinking laparoscopically and operating robotically with Versius, patients, surgeons and healthcare professionals can all benefit from the value that robotic MAS brings," said the company.

In addition, Versius captures data in its digital ecosystem to support surgeons' continuous learning. The Versius Connect app, Versius Trainer, and CMR clinical registry can provide numerous insights to ultimately improve surgical care, CMR Surgical said.

"My clinical practice consists of both complex cancer and high-volume urological procedures such as prostatectomies with and without lymphadenectomies, nephrectomies and cystectomies, so I need a versatile, adaptable tool that will support me across the breadth of my clinical practice, said Dr. Eric Potiron, a urologist at Clitnique Urologique Nantes-Atlantis. "Thanks to the versatility of the system, we have been able to establish an outpatient program for patients receiving radical prostatectomy using Versius."

Register today to save 40% on conference passes!

More than 70% of hospitals that have used Versius have used it across two or more specialties, said CMR Surgical. They range from urology, general surgery, and gynecology to thoracic surgery.

The company also has clinical trials under way for pediatric surgery and transoral robotic surgery (TORS) in the U.K. CMR is performing its pediatric trial in partnership with three clinical sites across the National Health System (NHS).

The primary site of the trial is the Department of Pediatric Urology at Southampton Children's Hospital. It was the first to perform pediatric urology surgery with Versius in a clinical trial.

Leading international journals have published clinical evidence on the use of Versius, said CMR Surgical. The FDA has granted marketing authorization for cholecystectomy.

With the latest product enhancements, CMR said it is focused on bringing the benefits of Versius to more hospitals, as it enters new markets to bring minimal access surgery to more patients around the world.

"With the Versius Plus offering including significant enhancements such as vLimeLite and the Ultrasonic Dissector, as well as landmark clinical trials, we are in a strong position to provide more patients with the benefits of robotic-assisted surgery," said Colella.